Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk? - Wikidata - wikimedia - TriplyDB

Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk?

Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk?

http://www.wikidata.org/entity/Q37583596

about

Pioglitazone in the treatment of type 2 diabetes: safety and efficacy review

P2860

Q36139056-2EADE0F8-263A-461F-950F-C48A03A3619F

P2860

Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk?

http://www.wikidata.org/entity/Q37583596

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Peroxisome proliferator-activa ...... increase cardiovascular risk?

@en

Peroxisome proliferator-activa ...... increase cardiovascular risk?

@nl

type

label

Peroxisome proliferator-activa ...... increase cardiovascular risk?

@en

Peroxisome proliferator-activa ...... increase cardiovascular risk?

@nl

prefLabel

Peroxisome proliferator-activa ...... increase cardiovascular risk?

@en

Peroxisome proliferator-activa ...... increase cardiovascular risk?

@nl

P1433

Q37583596-37B4CE9B-6D25-4369-ABD0-4094EFAF52BD

P1476

Q37583596-6F0938C9-A8FC-4490-BFA6-73E58F489C0E

P2093

Q37583596-04C9C4E5-63C1-4F74-9693-A89AD7535D6E

Q37583596-4FFD78AD-6C78-456C-92E8-075CC0502E71

Q37583596-CC8295AD-6C22-4BC1-A970-29E248067FF1

P2860

Q37583596-04F64086-B2E8-4D9B-96D5-EEC520754054

Q37583596-1067DD93-56C7-4D67-8C32-DC73E4A40EFB

Q37583596-186ADF81-2DC4-4FDC-AE86-66F0BC2B3207

Q37583596-1E2A15B5-DF48-4CCF-927C-DBD2B47490F9

Q37583596-23952FB7-FA4D-43A7-913E-71DCCCF06185

Q37583596-25062A9A-9B32-406C-A108-54E0F47DBEDA

Q37583596-2B384516-3CCF-4159-BC36-92E7DE11D77E

Q37583596-2E2298E2-4EF2-4567-BEF1-A637B772E67E

Q37583596-3365E5ED-D865-4274-9B8A-5CBB07FF9B60

Q37583596-367C8B20-ED61-4620-A16C-7D8B94C85404

P304

Q37583596-68A1E742-8F7A-4DAD-95A6-510989CA9567

P31

Q37583596-430A178D-49D4-4643-8FC6-D8A979A45E01

P356

Q37583596-21D38340-CCB7-416C-AD25-0328BEEAB3CD

P478

Q37583596-27693A90-8DF5-400B-BF26-3E1FABB9A28C

P577

Q37583596-D5CF6E9A-806A-42BB-BD98-5D565FB5DAC3

P5875

Q37583596-3BED8103-1EBF-4F9B-B4B1-9B24685BC72F

P698

Q37583596-9999C044-24B2-48B0-9AC8-8797229A2F16

P932

Q37583596-66E9C805-9B1E-4C1F-9DD5-9B82CC124856

P356

P1433

P1476

Peroxisome proliferator-activa ...... increase cardiovascular risk?

@en

P2093

Ahmad Aljada

http://www.w3.org/2001/XMLSchema#string

Kshitij Ashwin Shah

http://www.w3.org/2001/XMLSchema#string

Shaker A Mousa

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates

The PPARdelta agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

Proinflammatory cytokines regulate LOX-1 expression in vascular smooth muscle cells.

Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese.

Telmisartan, ramipril, or both in patients at high risk for vascular events.

P304

460764

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2009/460764

http://www.w3.org/2001/XMLSchema#string

P478

2009

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26757367

http://www.w3.org/2001/XMLSchema#string

P698

19696948

http://www.w3.org/2001/XMLSchema#string

P932

2729049

http://www.w3.org/2001/XMLSchema#string